Aviso: para depositar documentos, por favor, inicia sesión e identifícate con tu cuenta de correo institucional de la UCM con el botón MI CUENTA UCM. No emplees la opción AUTENTICACIÓN CON CONTRASEÑA
 

RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation

Citation

Ibáñez-Escribano A, Reviriego F, Vela N, Fonseca-Berzal C, Nogal-Ruiz JJ, Arán VJ, et al. Promising hit compounds against resistant trichomoniasis: Synthesis and antiparasitic activity of 3-(Ω-aminoalkoxy)-1-benzyl-5-nitroindazoles. Bioorganic & Medicinal Chemistry Letters [Internet]. abril de 2021 [citado 21 de enero de 2025];37:127843. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0960894X2100069X

Abstract

Ikaros family zinc finger protein 1 and 3 (IKZF1 and IKZF3) are transcription factors that promote multiple myeloma (MM) proliferation. The immunomodulatory imide drug (IMiD) lenalidomide promotes myeloma cell death via Cereblon (CRBN)- dependent ubiquitylation and proteasome-dependent degradation of IKZF1 and IKZF3. Although IMiDs have been used as first-line drugs for MM, the overall survival of refractory MM patients remains poor and demands the identification of novel agents to potentiate the therapeutic effect of IMiDs. Using an unbiased screen based on mass spectrometry, we identified the Runt-related transcription factor 1 and 3 (RUNX1 and RUNX3) as interactors of IKZF1 and IKZF3. Interaction with RUNX1 and RUNX3 inhibits CRBN-dependent binding, ubiquitylation, and degradation of IKZF1 and IKZF3 upon lenalidomide treatment. Inhibition of RUNXs, via genetic ablation or a small molecule (AI-10-104), results in sensitization of myeloma cell lines and primary tumors to lenalidomide. Thus, RUNX inhibition represents a valuable therapeutic opportunity to potentiate IMiDs therapy for the treatment of multiple myeloma

Research Projects

Organizational Units

Journal Issue

Description

Unesco subjects

Keywords

Collections